Eli Lilly has started Phase 3 trials of brenipatide (LY3537031) — a dual GIP/GLP-1 receptor agonist in the same class as tirzepatide — not for weight loss, but for alcohol use disorder and major depressive disorder. At Psych Congress 2026 in New Orleans this month, Lilly presented the Phase 1 data behind the program: 212 participants, weekly doses of 0.3 to 4.5 mg, no serious adverse events, and gastrointestinal side effects no higher than placebo.
That last number is the tell. Per Lilly's materials, brenipatide was designed for receptors in the brain's reward and inflammation pathways rather than the gut, at doses a fraction of tirzepatide's — and it is the clearest signal yet that the "GLP-1s for the brain" hypothesis the community has been discussing for two years is now a multi-billion-dollar pharma program. Efficacy in these indications has not yet been demonstrated.
Research-context information only. Brenipatide is an investigational compound with no marketing approval anywhere; it is not available inside or outside clinical trials except to enrolled participants, and possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Results described here come from conference presentations and company materials, not peer-reviewed efficacy publications. This article reports what has been documented, not what should be done. Research-use-only peptides sold by vendors are not FDA-approved for human use. Consult a licensed physician for personal medical decisions.
What Lilly Presented at Psych Congress 2026
The poster, presented September 2026 in New Orleans, covered the Phase 1 multiple-ascending-dose study J2S-MC-GZMD (NCT06606106) — the safety and dose-finding work that unlocked the Phase 3 program. Per Genetic Engineering & Biotechnology News and BioSpace's coverage, the study enrolled 212 participants across three cohorts spanning BMI 22 to 45, including dedicated Japanese and Chinese cohorts.
The numbers that matter:
| Measure | Brenipatide | Placebo |
|---|---|---|
| Weekly doses tested | 0.3 / 0.75 / 1.5 / 3 / 4.5 mg | — |
| Half-life | 9.08–12.5 days | — |
| Treatment-emergent adverse events | 57.6% | 42.9% |
| GI adverse events | 25% | 25% |
| Dysesthesia (abnormal skin sensations) | 15.2% | 0% |
| Serious adverse events / deaths | 0 | 0 |
| Discontinuation for adverse events | ~2% (4 participants) | — |
Two things stand out against the incretin drugs people actually use. First, the dose range: brenipatide tops out at 4.5 mg weekly, versus 15 mg for tirzepatide — consistent with a molecule built to hit central nervous system targets rather than drive maximal weight loss. Second, GI tolerability: nausea and its relatives are the defining side effect of every marketed GLP-1, yet brenipatide's GI event rate matched placebo exactly. The novel signal instead was dysesthesia — tingling or altered skin sensation — in roughly one in seven participants, absent from placebo.
Lilly's Robert Nicholson noted the half-life "allows us to have a durability of exposure that can go beyond the weekly dosing interval" — brenipatide's 9-to-12.5-day half-life roughly doubles tirzepatide's five days, keeping receptor exposure steady between weekly injections and potentially supporting longer intervals down the line.
The Phase 3 RENEW Program
Brenipatide skipped the obesity lane entirely. The Phase 3 program, per the trial registries, targets the brain:
- RENEW-ALC-1 and RENEW-ALC-2 (NCT07219966, NCT07219953) — two 56-week alcohol use disorder trials totaling roughly 2,200 participants across eight countries. The primary endpoint is change in drinking patterns measured by the Timeline Followback method — a harm-reduction framing, not lifelong-abstinence-or-failure. One trial covers moderate-to-severe AUD; the other covers AUD with hazardous drinking.
- RENEW-MDD-1 (NCT07412756) — roughly 1,000 participants across 14 countries with major depressive disorder, testing brenipatide plus standard of care against placebo plus standard of care on time to symptom relapse.
Behind those sit Phase 2 programs in opioid use disorder, tobacco use disorder, bipolar disorder, and schizophrenia, plus immunology plays in asthma, irritable bowel syndrome, and COPD — 13 Phase 2/3 studies in total. Per the trial registries and company guidance, topline alcohol data is expected around 2028.
Why This Validates the "GLP-1s for the Brain" Thesis
The reward-circuit story did not start with brenipatide. A 2025 JAMA Psychiatry randomized trial (PMID 39937469) found that low-dose weekly semaglutide reduced alcohol craving, drinking quantity, and heavy-drinking days versus placebo in adults with alcohol use disorder over nine weeks — with reductions in cigarettes per day as a bonus finding. A 2026 Lancet trial in AUD with comorbid obesity pointed the same direction. Observational datasets have linked GLP-1 exposure to lower rates of alcohol, opioid, and nicotine use disorders — the full picture is in our GLP-1 brain health and addiction synthesis.
What brenipatide changes is intent. Semaglutide's addiction data is a side effect being studied after the fact; Lilly describes brenipatide as a purpose-built molecule with amino-acid substitutions that resist the proteases that normally degrade GLP-1 analogs, aimed at reward and neuroinflammation circuitry from day one. The company that owns tirzepatide and retatrutide committing 13 mid-to-late-stage trials to the brain hypothesis moves it from community discussion into a pharma pipeline — though efficacy in these indications remains unproven.
What This Means for Peptide Buyers
Brenipatide itself changes nothing on the research market today — and that is the practical point worth being precise about:
- Brenipatide is not for sale, anywhere. No research vendor stocks LY3537031, and no gray-market version exists. Anything marketed under that name would be worth treating as counterfeit on sight.
- The purchasable compounds on these receptors are the familiar three. Semaglutide (GLP-1), tirzepatide (GIP/GLP-1 — brenipatide's direct class sibling), and retatrutide (GIP/GLP-1/glucagon) are all sold lyophilized by research suppliers, with live pricing compared across vendors in each guide and on /best/tirzepatide.
- The craving-reduction data that exists applies to semaglutide, at low doses. The JAMA Psychiatry trial used low-dose weekly semaglutide — not brenipatide, and not high-dose weight-loss protocols. That trial was conducted under clinical supervision with an approved product; it does not describe research-peptide products, which are not FDA-approved for any human use. Self-reported community accounts describe blunted interest in alcohol on GLP-1s — anecdotal, and outside any labeled indication.
- The dysesthesia signal is the one to follow. If a skin-sensation side effect at sub-5 mg doses recurs in Phase 3, it becomes the first tolerability trade-off unique to a brain-optimized incretin — something no currently sold compound shares.
Current deals and coupon codes across recommended suppliers are tracked on our deals page.
